Last updated: 15 June 2019 at 11:50am EST

Niranjan Sardesai Net Worth




The estimated Net Worth of Niranjan Sardesai is at least $382 Thousand dollars as of 4 January 2017. Niranjan Sardesai owns over 9,813 units of Inovio Pharmaceuticals Inc stock worth over $381,518 and over the last 15 years Niranjan sold INO stock worth over $0.

Niranjan Sardesai INO stock SEC Form 4 insiders trading

Niranjan has made over 6 trades of the Inovio Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Niranjan exercised 9,813 units of INO stock worth $60,056 on 4 January 2017.

The largest trade Niranjan's ever made was exercising 33,116 units of Inovio Pharmaceuticals Inc stock on 28 August 2016 worth over $202,670. On average, Niranjan trades about 4,446 units every 89 days since 2009. As of 4 January 2017 Niranjan still owns at least 58,247 units of Inovio Pharmaceuticals Inc stock.

You can see the complete history of Niranjan Sardesai stock trades at the bottom of the page.



What's Niranjan Sardesai's mailing address?

Niranjan's mailing address filed with the SEC is 11494 SORRENTO VALLEY ROAD, , SAN DIEGO, CA, 92121.

Insiders trading at Inovio Pharmaceuticals Inc

Over the last 19 years, insiders at Inovio Pharmaceuticals Inc have traded over $23,656,819 worth of Inovio Pharmaceuticals Inc stock and bought 1,958,377 units worth $5,174,071 . The most active insiders traders include Austin W & Greenhouse David..., Jong Joseph Kim, and Felix Theeuwes. On average, Inovio Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $745,390. The most recent stock trade was executed by Michael John Sumner on 30 June 2024, trading 2,917 units of INO stock currently worth $19,106.



What does Inovio Pharmaceuticals Inc do?

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.



What does Inovio Pharmaceuticals Inc's logo look like?

Inovio Pharmaceuticals Inc logo

Complete history of Niranjan Sardesai stock trades at Inovio Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
4 Jan 2017 Niranjan Sardesai
Sr. VP Research and Development
Option 9,813 $6.12 $60,056
4 Jan 2017
58,247
28 Aug 2016 Niranjan Sardesai
Sr. VP Research and Development
Option 33,116 $6.12 $202,670
28 Aug 2016
70,234
30 Sep 2015 Niranjan Sardesai
Sr. VP Research and Development
Buy 4,000 $5.50 $22,000
30 Sep 2015
32,000
12 Aug 2014 Niranjan Sardesai
Sr. VP Research and Development
Buy 2,550 $8.70 $22,185
12 Aug 2014
28,000
20 Mar 2013 Niranjan Sardesai
Sr. VP Research and Development
Buy 25,000 $0.53 $13,250
20 Mar 2013
101,800
16 May 2012 Niranjan Sardesai
Sr. VP Research and Development
Buy 10,000 $0.45 $4,500
16 May 2012
76,800


Inovio Pharmaceuticals Inc executives and stock owners

Inovio Pharmaceuticals Inc executives and other stock owners filed with the SEC include: